Sugi Predict

Sugi Predict / Compounds / SCHEMBL2390665

SCHEMBL2390665

SCHEMBL2390665

COC(=O)Cc1ccc(B2OC(C)(C)C(C)(C)O2)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AAK1 Q2M2I8 1/20 0.44
▸ ROCK1 Q13464 1/20 0.43
▸ DGAT1 O75907 1/20 0.40
▸ HIF1A Q16665 4/20 0.40
▸ LIPG Q9Y5X9 3/20 0.37
▸ CA1 P00915 3/20 0.36
▸ CA2 P00918 3/20 0.36
▸ CA9 Q16790 3/20 0.36
▸ LPL P06858 2/20 0.36
▸ PRMT5 O14744 1/20 0.36
▸ WDR77 Q9BQA1 1/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HTT P42858 2/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ THRB P10828 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ CA12 O43570 1/20 0.36
▸ CA3 P07451 1/20 0.36
▸ CA4 P22748 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29536974 1.00 AAK1 (0.44) AAK1ROCK1DGAT1HIF1ALIPG
SCHEMBL14711661 0.88 ROCK1 (0.44) AAK1ROCK1DGAT1HIF1ALIPG
SCHEMBL16415342 0.87 ROCK1 (0.42) AAK1ROCK1HIF1ALIPGLPL
SCHEMBL20562401 0.85 HIF1A (0.44) AAK1ROCK1DGAT1HIF1ALIPG
SCHEMBL27176829 0.85 HIF1A (0.48) ROCK1DGAT1HIF1ALIPGCA1
SCHEMBL5263766 0.85 ROCK1 (0.46) AAK1ROCK1DGAT1HIF1ALIPG
SCHEMBL24526366 0.84 ROCK1 (0.46) AAK1ROCK1DGAT1HIF1ALIPG
SCHEMBL14710834 0.84 ROCK1 (0.60) AAK1ROCK1DGAT1HIF1ALIPG
SCHEMBL29743675 0.84 ROCK1 (0.46) AAK1ROCK1DGAT1HIF1ALIPG
SCHEMBL24410085 0.84 ROCK1 (0.43) AAK1ROCK1DGAT1HIF1ALIPG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORP (US) 2023-09-28 — — US disclosed
CN-116710453-A Kinase inhibitors and uses thereof 璧辰医药技术股份有限公司 2023-09-05 — — CN disclosed
EP-4192582-A1 KINASE INHIBITORS AND USES THEREOF ABM Therapeutics Corporation (US) 2023-06-14 — — EP disclosed
WO-2022032071-A1 KINASE INHIBITORS AND USES THEREOF ABM THERAPEUTICS CORPORATION (US) 2022-02-10 — — WO disclosed
EP-3027602-A1 NOVEL DERIVATIVES OF INDOLE AND PYRROLE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME Les Laboratoires Servier (FR) 2016-06-08 — — EP disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 — — US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 — — US disclosed
WO-2015011252-A1 PYRIMIDINE-PYRIDINONE SERINE/THREONINE KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2015-01-29 — — WO disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 — — US disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 — — WO disclosed
US-8013001-B2 Modulators of LXR EXELIXIS, INC. (US) 2011-09-06 — — US disclosed
US-20100056582-A1 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2010-03-04 — — US disclosed
US-7482366-B2 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2009-01-27 — — US disclosed
US-20080119488-A1 Modulators Of Nuclear Receptors EXELIXIS, INC. (US) 2008-05-22 — — US disclosed
EP-1773337-A2 MODULATORS OF NUCLEAR RECEPTORS Exelixis, Inc. (US) 2007-04-18 — — EP disclosed
WO-2006025979-A9 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS INC (US) 2006-04-20 — — WO disclosed
WO-2006025979-A2 MODULATORS OF NUCLEAR RECEPTORS EXELIXIS, INC. (US) 2006-03-09 — — WO disclosed
US-20050080111-A1 Modulators of LXR X-CEPTOR THERAPEUTICS, INC. (US) 2005-04-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303570-A1 KINASE INHIBITORS AND USES THEREOF ERBB2, ERBB3, ERBB4 AAK1 299/4885ROCK1 225/4885DGAT1 4818/4885
US-20080119488-A1 Modulators Of Nuclear Receptors NR1H2, NR0B1, NR1H3 AAK1 2751/4885ROCK1 2696/4885DGAT1 3233/4885
US-20050080111-A1 Modulators of LXR NR1H2, NR1H3, NR1H4 AAK1 2456/4885ROCK1 1411/4885DGAT1 786/4885
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 AAK1 1297/4885ROCK1 1820/4885DGAT1 371/4885
US-20100056582-A1 Modulators of LXR NR1H2, NR1H3, NR1H4 AAK1 2456/4885ROCK1 1411/4885DGAT1 786/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.